(0.05%) 5 519.75 points
(0.11%) 39 888 points
(0.15%) 19 781 points
(-0.06%) $81.58
(0.64%) $2.83
(-0.26%) $2 338.20
(0.08%) $29.55
(0.39%) $1 005.70
(0.04%) $0.932
(-0.07%) $10.53
(0.00%) $0.788
(-0.85%) $87.25
0.57% $ 22.93
Live Chart Being Loaded With Signals
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA)...
Stats | |
---|---|
Dzisiejszy wolumen | 50 899 |
Średni wolumen | 27 036 |
Kapitalizacja rynkowa | 71.68M |
EPS | $-1.430 ( Q1 | 2024-05-09 ) |
Następna data zysków | ( $-1.000 ) 2024-08-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-5.73 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0300 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-23 | Mayleben Timothy M | Sell | 1 800 | Stock Option (right to buy) |
2024-05-23 | Mayleben Timothy M | Sell | 1 800 | Stock Option (right to buy) |
2024-05-23 | Girao Tiago | Sell | 1 800 | Stock Option (right to buy) |
2024-05-23 | Girao Tiago | Sell | 1 800 | Stock Option (right to buy) |
2024-05-23 | Girao Tiago | Sell | 1 800 | Stock Option (right to buy) |
INSIDER POWER |
---|
92.63 |
Last 91 transactions |
Buy: 68 384 799 | Sell: 4 151 295 |
Wolumen Korelacja
Landos Biopharma, Inc. Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
CDXC | 0.975 |
FUSN | 0.963 |
ACTG | 0.959 |
VTVT | 0.956 |
GERN | 0.951 |
PESI | 0.95 |
SIGA | 0.947 |
IVCB | 0.947 |
DXPE | 0.946 |
EML | 0.943 |
10 Najbardziej negatywne korelacje | |
---|---|
MTEM | -0.965 |
BTTX | -0.962 |
NLSP | -0.958 |
LUNA | -0.958 |
RCMT | -0.957 |
IMRX | -0.956 |
AZ | -0.953 |
CMTL | -0.949 |
HNRG | -0.947 |
RMGC | -0.94 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Landos Biopharma, Inc. Korelacja - Waluta/Towar
Landos Biopharma, Inc. Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-3.50 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-3.50 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-577 000 (0.00 %) |
EPS: | $-9.44 |
FY | 2021 |
Przychody: | $18.00M |
Zysk brutto: | $18.00M (100.00 %) |
EPS: | $-0.981 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Landos Biopharma, Inc.
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej